adding memantine to treatment of schozopherenia

Adjunctive Memantine Therapy for Negative Symptoms in Schizophrenia: A Double-Blind Placebo Controlled Study

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180301038906N1

Enrollment

Registered

2018-06-10

Start date

2015-04-01

Completion date

Unknown

Last updated

2018-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

schizopherenia. Schizophrenia

Interventions

Intervention 1: Intervention group: For patients, a daily dose of 5 mg of memantine was started, with a dose of 5 mg a week to reach 20 mg / day (in two doses)..Patients in both groups "had an atypica

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Schizophrenia in the relative recovery period Use of atypical antipsychotics including risperidone and olanzapine No other drugs (except anticholinergic and benzodiazepine) Lack of pregnancy or breastfeeding No serious organic disease and no drug use at the time of entering the study

Exclusion criteria

Exclusion criteria: There is serious organic disease Pregnancy or breastfeeding Existence of dementia

Design outcomes

Primary

Measure	Time frame
The condition of psychotic symptoms. Timepoint: Week 2,4,6. Method of measurement: wechsler.	—

Secondary

Measure	Time frame
Cognitive and negative symptoms. Timepoint: week 2,4,6. Method of measurement: wechsler.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRaheleh Jahantigh

Mashhad University of Medical Sciences

MohammadzadehA931@mums.ac.ir+98 989157030782

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026